Galapagos names new CFO

Belgium's Galapagos announced the appointment of Guillaume Jetten as chief financial officer. Jetten succeeds Leo Steenbergen, who will continue to serve as Galapagos' CFO until July and will assist in the transition process. The company also approved Dr. Werner Cautreels' appointment to the board of directors. 

IGI Laboratories named Hem Pandya its new president and CEO.

Compugen announced the appointment of Anat Cohen-Dayag, Ph.D. and Martin Gerstel as co-CEOs of the company.

Pacific Biosciences has appointed Eric Schadt as its new chief scientific officer.

Endo Pharmaceuticals said that the company is granting Alan Levin a sign-on award of 43,500 restricted stock units and an option to purchase 80,000 shares of Endo common stock in connection with his appointment as Endo's executive vice president and chief financial officer.

Mylan has appointed Jolene Varney as its new executive vice president and CFO.

Lexicon Pharmaceuticals named Ajay Bansal as executive vice president, corporate development and chief financial officer.

Bionovo announced the appointment of Klaus Kohl, Ph.D., as senior vice president and chief technical officer.

GENEART has named Daniel Seibert as chief financial officer and a member of the company's management board.

Catalent Pharma Solutions named Steve Leonard as senior vice president of global operations.

Astellas Pharma US recently hired Dan Dunham as the vice president of compliance.

King Pharmaceuticals has appointed John Howarth as its new vice president of investor relations.

PTC Therapeutics announced that Clare Kennedy has been appointed as vice president of commercial operations.

Astellas Pharma US recently hired Dan Dunham as the vice president of compliance.

Cequent Pharmaceuticals has promoted F. Stephen Laroux, Ph.D., to the new position of director, immunology and inflammatory diseases,

HepaLife Technologies announced the appointment of four additional distinguished liver experts to its Advisory Board. They are: Achilles A. Demetriou;; Fredric D. Gordon; Philip Rosenthal and John M. Vierling.

Eli Lilly and Company board elected R. David Hoover as a new member.

Diasome Pharmaceuticals added Arthur H. Rubenstein, MBBCh, and G. Alexander (Zan) Fleming, MD, to the company's board of directors.

Pennsylvania Bio announced the appointment of three new members to its Board of Directors: Michael F. Cola, president, Specialty Pharmaceuticals, Shire plc; Stephen A. Jannetta, Esq., partner, Morgan, Lewis & Bockius LLP; and Kim Taylor, president, Centocor Ortho Biotech Inc

HemaCare Corporation appointed Steven B. Gerber, M.D. as its chairman.

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.